Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

NCT04727541 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class

Stopped Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine plus cisplatin, that was discontinued as it was unlikely to meet the primary endpoint of OS, the recruitment for this study was stopped prematurely.

Conditions

Interventions

Sponsor

AIO-Studien-gGmbH

Collaborators